Showing 1321-1330 of 7115 results for "".
Scientifically Speaking: Optimizing Results with PRP
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-optimizing-results-with-prp/20034/As increasing evidence shows the benefits of PRP for hair loss, more practices are adding it to their menu. But the results of treatment can vary depending on numerous factors. Glynis Ablon, MD and Jeffrey Rapaport, MD talk to host Joel L. Cohen, MD about their approach and share expert tips to optiDermWireTV: SPF Accuracy, Dupixent PN Data, AD Pipeline
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-spf-accuracy-dupixent-pn-data-ad-pipeline/20009/Researchers from the Environmental Working Group say that many sunscreens offer less than half their stated SPF protection against UVB. The Thriving in Aesthetics educational series featuring Sabrina Fabi, MD and Steven Dayan, MD is returning with a focus on diversity in aesthetics. As eczema awareDermWireTV: Incyte's Opzelura, BMS Patient Week, Science of Skincare Summit
https://practicaldermatology.com/topics/psoriasis/dermwiretv-incytes-opzelura-bms-patient-week-science-of-skincare-summit/20003/Incyte’s Opzelura is the first topical JAK inhibitor approved in the US. Lawrence Eichenfield, MD weighs in on the cream formulation of ruxolitinib for treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older. Bristol Myers Squibb's seventh Global PAll About Innovations at DERM2021
https://practicaldermatology.com/series/dermatology-education-foundation/all-about-innovations-at-derm2021/19965/Whether you’re a new or experienced learner in the dermatology PA/NP space, Sandri Johnson, FNP-BC, says the DERM2021 NP/PA CME Conference has something to offer. Attendees will learn about the latest innovations in the field.Opportunities and Barriers in Teledermatology
https://practicaldermatology.com/conferences/aad-2021/opportunities-and-barriers-in-teledermatology/19923/Dermatologists' participation in telemedicine has increased exponentially over the past year. But what does the future hold? What opportunities exist and what challenges remain? Jules Lipoff, MD weighs in.Update on Hormonal Replacement and the Skin
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/update-on-hormonal-replacement-and-the-skin/19886/A review of the science shows that hormone replacement can be both safe and effective for optimal cutaneous health. Ron Moy, MD reviews his presentation from San Diego Dermatology Symposium.Scientifically Speaking: Can We Conquer Cellulite?
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-can-we-conquer-cellulite/19872/Treating cellulite has been a challenge, but new and emerging technologies offer hope to overcome this common condition. Host Joel L. Cohen, MD talks with Nazanin Saedi, MD, Endo's Mike McLane, PhD, and Soliton's Wally Klemp.Conversations in Acne, Part 1
https://practicaldermatology.com/topics/acne-rosacea/conversations-in-acne-part-1/19867/As treatment options for acne expand, clinicians consider the potential to combine topical therapies or pair topicals with systemics, all while adhering to guidelines for care and prescribing antibiotics responsibly. In the first episode of this three-part series, host Neal Bhatia, MD speaks with HiDermWireTV: LEO Science & Tech Hub, Allergan/SkinBetter DREAM Initiative, San Diego Dermatology Symposium
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-leo-pharma-science-tech-hub-allerganskinbetter-dream-initiative-san-diego-dermatology-symposium/19856/Innovation Endeavors and the LEO Science & Tech Hub kick off a Deep Life Challenge program. Allergan Aesthetics, an AbbVie company, and Skinbetter Science launch a new long-term, educational initiative: The DREAM (Driving Racial Equity in Aesthetic Medicine) Initiative. The San Diego DermatologyIL-23 Inhibitors: Update on Safety and Dosing
https://practicaldermatology.com/topics/psoriasis/il-23-inhibitors-update-on-safety-and-dosing/19773/With more experience using IL-23 inhibitors to treat psoriasis, dermatologists are seeing high levels of patient satisfaction and no new safety signals. Jennifer Cather, MD assesses the clinical experience.